Surgical Tweak For Treatment Of Oral Submucous Fibrosis – A Clinical Study Technical Tweak In Surgry For Treatment Of Oral Submucous Fibrosis – A Clinical Study

Authors

  • Dr. Matariya Ridhi , Dr. Misra Gyanendra , Dr. Jain Sanchit , Dr. Patel Prarthana , Dr. Kalpesh Vaishnav , Dr. Patel Mili

DOI:

https://doi.org/10.47750/pnr.2022.13.S05.453

Abstract

Aim: The study was aimed at evaluating the efficacy of modified technique for treatment of Grade III and Grade IV oral submucous fibrosis. Postoperative mouth opening and cheek flexibility after surgical intervention was evaluated after 6 months.

Materials and Methods: A total of 5 patients with oral submucous fibrosis with reduced mouth opening were included in the study. The patients were operated and modified technique was incorporated to interpose the defect created after fibrotomy. The modified technique used buccal fat pad to cover the posterior defect and Split thickness skin graft to cover the defect anteriorly till the corner of mouth. The patients were evaluated for mouth opening and cheek flexibility postoperatively and followed up after 6 months. All these data were recorded and evaluated for success.

Results: The three-finger mouth opening was successfully achieved in all the five patients. The discomfort of the patient was minimum. Only 1 patient showed delayed healing out of 5 patients. Burning sensation of mouth along with other symptoms of OSMF were reduced.

Conclusion: The modification technique used for interposition after fibrotomy in OSMF is overall a better modality for treatment of oral lesions as it is more acceptable by the patient. The procedure though has shown to have faster recovery needs further comparison with gold standard nasolabial flap for interposition.  

Downloads

Published

2022-05-01 — Updated on 2022-05-01

Issue

Section

Articles

How to Cite

Surgical Tweak For Treatment Of Oral Submucous Fibrosis – A Clinical Study Technical Tweak In Surgry For Treatment Of Oral Submucous Fibrosis – A Clinical Study. (2022). Journal of Pharmaceutical Negative Results, 13, 3040-3046. https://doi.org/10.47750/pnr.2022.13.S05.453